T K Choueiri1, S K Pal2, D F McDermott3, S Morrissey4, K C Ferguson5, J Holland5, W G Kaelin4, J P Dutcher6. 1. Dana-Farber Cancer Institute and Harvard Medical School, Kidney Cancer Program, Boston Toni_Choueiri@dfci.harvard.edu. 2. Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte. 3. Dana-Farber Cancer Institute and Harvard Medical School, Kidney Cancer Program, Boston Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston. 4. Dana-Farber Cancer Institute and Harvard Medical School, Kidney Cancer Program, Boston. 5. Clinical Development, Exelixis Inc., South San Francisco. 6. St Luke's-Roosevelt Hospital Center, New York, USA.
Abstract
BACKGROUND: Cabozantinib targets tyrosine kinases including the hepatocyte growth factor receptor (MET) and vascular endothelial growth factor (VEGF) receptor 2, which are important drug targets in renal cell carcinoma (RCC). PATIENTS AND METHODS: This single-arm open-label phase I trial evaluated the safety and tolerability of cabozantinib in heavily pretreated patients with metastatic clear cell RCC. RESULTS: The study enrolled 25 RCC patients for whom standard therapy had failed. Patients received a median of two prior systemic agents, and most patients had previously received at least one VEGF pathway inhibiting therapy (22 patients [88%]). Common adverse events included fatigue, diarrhea, nausea, proteinuria, appetite decreased, palmar-plantar erythrodysesthesia, and vomiting. Partial response was reported in seven patients (28%). Median progression-free survival was 12.9 months, and median overall survival was 15.0 months. CONCLUSION: Cabozantinib demonstrates preliminary anti-tumor activity and a safety profile similar to that seen with other multitargeted VEGFR tyrosine kinase inhibitors in advanced RCC patients. Further evaluation of cabozantinib in RCC is warranted. ClinicalTrials.gov identifier: NCT01100619.
BACKGROUND:Cabozantinib targets tyrosine kinases including the hepatocyte growth factor receptor (MET) and vascular endothelial growth factor (VEGF) receptor 2, which are important drug targets in renal cell carcinoma (RCC). PATIENTS AND METHODS: This single-arm open-label phase I trial evaluated the safety and tolerability of cabozantinib in heavily pretreated patients with metastatic clear cell RCC. RESULTS: The study enrolled 25 RCCpatients for whom standard therapy had failed. Patients received a median of two prior systemic agents, and most patients had previously received at least one VEGF pathway inhibiting therapy (22 patients [88%]). Common adverse events included fatigue, diarrhea, nausea, proteinuria, appetite decreased, palmar-plantar erythrodysesthesia, and vomiting. Partial response was reported in seven patients (28%). Median progression-free survival was 12.9 months, and median overall survival was 15.0 months. CONCLUSION:Cabozantinib demonstrates preliminary anti-tumor activity and a safety profile similar to that seen with other multitargeted VEGFR tyrosine kinase inhibitors in advanced RCCpatients. Further evaluation of cabozantinib in RCC is warranted. ClinicalTrials.gov identifier: NCT01100619.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: F Michael Yakes; Jason Chen; Jenny Tan; Kyoko Yamaguchi; Yongchang Shi; Peiwen Yu; Fawn Qian; Felix Chu; Frauke Bentzien; Belinda Cancilla; Jessica Orf; Andrew You; A Douglas Laird; Stefan Engst; Lillian Lee; Justin Lesch; Yu-Chien Chou; Alison H Joly Journal: Mol Cancer Ther Date: 2011-09-16 Impact factor: 6.261
Authors: Robert J Motzer; Bernard Escudier; Stephane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Andrea Kay; Alain Ravaud Journal: Cancer Date: 2010-09-15 Impact factor: 6.860
Authors: Rossella Elisei; Martin J Schlumberger; Stefan P Müller; Patrick Schöffski; Marcia S Brose; Manisha H Shah; Lisa Licitra; Barbara Jarzab; Viktor Medvedev; Michael C Kreissl; Bruno Niederle; Ezra E W Cohen; Lori J Wirth; Haythem Ali; Colin Hessel; Yifah Yaron; Douglas Ball; Barry Nelkin; Steven I Sherman Journal: J Clin Oncol Date: 2013-09-03 Impact factor: 44.544
Authors: B Beuselinck; S Oudard; O Rixe; P Wolter; A Blesius; J Ayllon; R Elaidi; P Schöffski; E Barrascout; A Morel; B Escudier; H Lang; J Zucman-Rossi; J Medioni Journal: Ann Oncol Date: 2010-10-11 Impact factor: 32.976
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Lauren C Harshman; Georg A Bjarnason; Ulka N Vaishampayan; Mary Mackenzie; Lori Wood; Frede Donskov; Min-Han Tan; Sun-Young Rha; Neeraj Agarwal; Christian Kollmannsberger; Brian I Rini; Toni K Choueiri Journal: Lancet Oncol Date: 2013-01-09 Impact factor: 41.316
Authors: Barbara Sennino; Toshina Ishiguro-Oonuma; Ying Wei; Ryan M Naylor; Casey W Williamson; Vikash Bhagwandin; Sebastien P Tabruyn; Weon-Kyoo You; Harold A Chapman; James G Christensen; Dana T Aftab; Donald M McDonald Journal: Cancer Discov Date: 2012-02-24 Impact factor: 39.397
Authors: Matthew R Smith; Christopher J Sweeney; Paul G Corn; Dana E Rathkopf; David C Smith; Maha Hussain; Daniel J George; Celestia S Higano; Andrea L Harzstark; A Oliver Sartor; Nicholas J Vogelzang; Michael S Gordon; Johann S de Bono; Naomi B Haas; Christopher J Logothetis; Aymen Elfiky; Christian Scheffold; A Douglas Laird; Frauke Schimmoller; Ethan M Basch; Howard I Scher Journal: J Clin Oncol Date: 2014-09-15 Impact factor: 44.544
Authors: Toni K Choueiri; Bernard Escudier; Thomas Powles; Paul N Mainwaring; Brian I Rini; Frede Donskov; Hans Hammers; Thomas E Hutson; Jae-Lyun Lee; Katriina Peltola; Bruce J Roth; Georg A Bjarnason; Lajos Géczi; Bhumsuk Keam; Pablo Maroto; Daniel Y C Heng; Manuela Schmidinger; Philip W Kantoff; Anne Borgman-Hagey; Colin Hessel; Christian Scheffold; Gisela M Schwab; Nizar M Tannir; Robert J Motzer Journal: N Engl J Med Date: 2015-09-25 Impact factor: 91.245
Authors: Rena C Zuo; Andrea B Apolo; John J DiGiovanna; Howard L Parnes; Corrine M Keen; Swati Nanda; William L Dahut; Edward W Cowen Journal: JAMA Dermatol Date: 2015-02 Impact factor: 10.282
Authors: Sumanta Pal; Arun Azad; Shailender Bhatia; Harry Drabkin; Brian Costello; John Sarantopoulos; Ravindran Kanesvaran; Richard Lauer; Alexander Starodub; Ralph Hauke; Christopher J Sweeney; Noah M Hahn; Guru Sonpavde; Stephen Richey; Timothy Breen; Gabriel Kremmidiotis; Annabell Leske; Elizabeth Doolin; David C Bibby; Jeremy Simpson; Jose Iglesias; Thomas Hutson Journal: Clin Cancer Res Date: 2015-03-18 Impact factor: 12.531